Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.
View all episodes
